Psychosocial/survivorship issues in breast cancer: Are we doing better?

Journal of the National Cancer Institute

Volumn 107, Issue 1, 2015, Pages

  Fallowfield, Lesley ^a   Jenkins, Valerie ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADL DISABILITY; AXILLARY LYMPH NODE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER SURVIVOR; COGNITIVE DEFECT; COGNITIVE THERAPY; COLD SWEAT; DYSPAREUNIA; FATIGUE; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; INTERPERSONAL COMMUNICATION; LIBIDO DISORDER; LYMPHEDEMA; MORBIDITY; NIGHT SWEAT; PATIENT DECISION MAKING; PELVIC FLOOR MUSCLE TRAINING; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAXATION TRAINING; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; SYSTEMATIC REVIEW (TOPIC); VAGINA DISCHARGE; VAGINAL DRYNESS; ADRENERGIC SYSTEM; AFFECTIVE SYMPTOMS; ANXIETY; BREAST NEOPLASMS; CASE CONTROL STUDY; DEPRESSION; DOCTOR PATIENT RELATION; DRUG EFFECTS; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HEALTH STATUS; IATROGENIC DISEASE; MENTAL STRESS; MILD COGNITIVE IMPAIRMENT; PATHOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVENTION AND CONTROL; PSYCHOLOGY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SURVIVOR; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AFFECTIVE SYMPTOMS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANXIETY; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COMMUNICATION; DEPRESSION; DYSPAREUNIA; EVIDENCE-BASED MEDICINE; FATIGUE; FEMALE; HEALTH STATUS; HUMANS; IATROGENIC DISEASE; LYMPHEDEMA; MILD COGNITIVE IMPAIRMENT; NEOPLASM RECURRENCE, LOCAL; PHYSICIAN-PATIENT RELATIONS; PRACTICE GUIDELINES AS TOPIC; QUALITY INDICATORS, HEALTH CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STRESS, PSYCHOLOGICAL; SURVIVORS; VASOMOTOR SYSTEM;

EID: 84925546643     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju335     Document Type: Review

References (40)

1. Ganz PA, Levit LA. Charting a New Course for the Delivery of High Quality Cancer Care. J Clin Onc. 2013;31(36):4485-4487.
2. Burgess C, Cornelius V, Love S, Graham J, Richards M, Ramirez A. Depression and anxiety in women with early breast cancer: Five year observational cohort study. BMJ. 2005;330(7493):702-705.
3. Mitchell AJ, Ferguson DW, Gill J, et al. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol. 2011;12:160-174.
4. Hall A, A'Hern R, Fallowfield L. Are we using appropriate self-report questionnaires for detecting anxiety and depression in women with early breast cancer? Eur J Ca. 1999;35:79-85.
5. Glaser AW, Fraser LK, Corner J, et al. Patient-reported outcomes of cancer survivors in England 15 years after diagnosis: a cross-sectional survey. BMJ Open. 2013;3:e002317.
6. Andersen BL, De Rubeis RJ, Berman BS, et al. Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer: An American Society of Clinical Oncology Guideline Adaptation. J Clin Oncol. 2014;32:1605-1619.
7. Hoffman CJ, Ersser SJ, Hopkinson JB, Nicholls PG, Harrington JE, Thomas PW. Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial. J Clin Oncol. 2012;30(12):1335-1342.
8. Chandwani KD, Perkins G, Nagendra HR, et al. Randomized, Controlled Trial of Yoga in Women With Breast Cancer Undergoing Radiotherapy. J Clin Oncol. 2014:1058-1065.
9. Di Sipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphedema after breast cancer: a systematic review and meta-analysis. Lancet Onc. 2013;14(6):500-515.
10. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95(3):279-293.
11. Dayes I, Whelan TJ, Julian JA, et al. Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer. J Clin Oncol. 2013;31:3758-3763.
12. Bower JE, Ganz P, Desmond KA, Rowland JH, Meyerowitz, Belin TR. Fatigue in breast cancer survivors: Occurrence, correlates and impact on quality of life. J Clin Oncol. 2000;18:743-753.
13. Bower JE, Lamkin DM. Inflammation and cancer related fatigue: mechanisms, contributing factors and treatment implications. Brain Beh Imm. 2013;30(Suppl):S48-S57.
14. Cramp F, Byron-Daniel J. Exercise for the management of cancer related fatigue in adults. Cochrane Database of Syst Rev. 2012;11:CD006145.
15. Wolin KY, Schwartz AL, Matthews CE, Courneya KS, Schmitz KH. Implementing the exercise guidelines for cancer survivors. J Support Onc. 2012;10(5):171-177.
16. Bower JE, Bak K, Berger A, et al. Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation. J Clin Oncol. 2014;32:1840-1850.
17. Caldos C, Tannock IF. Breast Cancer: Tamoxifen - when more might be better. Nat Rev Clin Onc. 2013;10:125-126.
18. Fallowfield L, Atkins L, Catt S, et al. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol. 2006;17:205-210.
19. Fellowes D, Fallowfield LJ, Saunders CM, Houghton J. Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'welltolerated' treatments? Breast Cancer Res Treat. 2001;66(1):73-81.
20. Coombes C, Bliss J, Hall E, Fallowfield LJ. Under-reporting of symptoms in patients with early breast cancer who have received tamoxifen treatment for 2-3 years. Proc Am Soc Clin Onc. 2003;22:13 (Abstract 48).
21. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100(3):273-284.
22. Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev. 2010;9:CD004923.
23. Mann E, Smith MJ, Hellier J, et al. Cognitive behavioral treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13(3):309-318.
24. Panjari M, Bell RJ, Davis SR. Sexual function after breast cancer. J Sex Med. 2011;8:294-302.
25. Juraskova I, Jarvis S, Mok K, et al. The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. J Sex Med. 2013;10(10):2549-2558.
26. Shilling V, Jenkins V, Solis-Trapala I The (mis) classification of chemo-fog: methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2006;95(2):125-129.
27. Hermelink K, Untch M, Lux MP, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal study Cancer. 2007;109(9); 1905-1913.
28. Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of post-menopausal patients with breast cancer: Results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. JCO. 2010;28(8):1294-1300.
29. Jenkins V, Amroisine L, Atkins L, Cuzick J, Howell A, Fallowfield LJ. Effects of Anastrozole on cognitive performance in postmenopausal women: a randomized, double-blind chemoprevention trial (IBIS II). Lancet Oncol. 2008;9(10):953-961.
30. Ganz PA, Kwan L, Castellon SA, et al. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst. 2013;105(11):791-801.
31. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703-708.
32. Reid-Arndt SA, Cox CR. Stress, coping and cognitive deficits in women after surgery for breast cancer. J Clin Psychol Med Settings. 2012;19(2):127-137.
33. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapyinduced cognitive changes. Nature Rev Cancer. 2007;7(3):192-201.
34. Janelsins, MC, Mustian KM, Palesh OG, et al. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: Implications for cognitive impairment research. Support Care Cancer. 2012;20(4):831-839.
35. McDonald BC, Saykin AJ, McAllister TW. Functional MRI of mild traumatic brain injury (mTBI): Progress and perspectives from the first decade of studies. Brain Imaging Behav. 2012;6(2):193-207.
36. Scherling C, Collins B, MacKenzie J, Bielajew C, Smith A. Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: A functional magnetic resonance imaging study. J Clin Exp Neuropsychol. 2012;34(5):543-560.
37. O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions (review). Cochrane Database Syst Rev. 2009; (3): CD001431.
38. Mayer M. Lessons Learned from the Metastatic Breast Cancer Community. Sem in Onc Nurs. 2010;3:195-202.
39. Mosher CE, DuHamel KN, Lam J, et al. Randomized trial of expressive writing for distressed metastatic breast cancer patients. Psychol Health. 2012;27:88-100.
40. Jacobsen PB, Wagner LI. A new quality standard: The integration of psychosocial care into routine cancer care. J Clin Oncol. 2012;30:1154-1159.